- Home
- PALI vs QNRX Comparison
PALI vs QNRX Comparison
Compare PALI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- QNRX
- Stock Information
- Founded
- PALI 1996
- QNRX 2018
- Country
- PALI United States
- QNRX United States
- Employees
- PALI N/A
- QNRX N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- QNRX Medical/Dental Instruments
- Sector
- PALI Health Care
- QNRX Health Care
- Exchange
- PALI Nasdaq
- QNRX Nasdaq
- Market Cap
- PALI 5.9M
- QNRX 4.8M
- IPO Year
- PALI N/A
- QNRX N/A
- Fundamental
- Price
- PALI $2.00
- QNRX $8.19
- Analyst Decision
- PALI Strong Buy
- QNRX
- Analyst Count
- PALI 2
- QNRX 0
- Target Price
- PALI $12.00
- QNRX N/A
- AVG Volume (30 Days)
- PALI 16.1M
- QNRX 134.4K
- Earning Date
- PALI 11-11-2025
- QNRX 11-06-2025
- Dividend Yield
- PALI N/A
- QNRX N/A
- EPS Growth
- PALI N/A
- QNRX N/A
- EPS
- PALI N/A
- QNRX N/A
- Revenue
- PALI N/A
- QNRX N/A
- Revenue This Year
- PALI N/A
- QNRX N/A
- Revenue Next Year
- PALI N/A
- QNRX N/A
- P/E Ratio
- PALI N/A
- QNRX N/A
- Revenue Growth
- PALI N/A
- QNRX N/A
- 52 Week Low
- PALI $0.53
- QNRX $5.01
- 52 Week High
- PALI $4.32
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- PALI 74.50
- QNRX 57.03
- Support Level
- PALI $1.64
- QNRX $7.19
- Resistance Level
- PALI $2.28
- QNRX $7.92
- Average True Range (ATR)
- PALI 0.23
- QNRX 0.44
- MACD
- PALI 0.12
- QNRX 0.04
- Stochastic Oscillator
- PALI 69.67
- QNRX 82.59
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.